Disease · MONDO_0004980

atopic eczema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. atopic eczema. Diseases, record MONDO_0004980. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004980

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: atopic eczema; Open Targets
Open Targets ID: MONDO_0004980; Open Targets
Other names: AD, ATOD, Atopic Dermatitides, Atopic Neurodermatitides, Atopic Neurodermatitis, Atopic dermatitis and related conditions (disorder), Dermatitides, Atopic, Disseminated Neurodermatitides, Disseminated Neurodermatitis, Eczema, Infantile, Eczematoid dermatitis, Infantile Eczema, Neurodermatitides, Atopic, Neurodermatitides, Disseminated, Neurodermatitis, Atopic, Neurodermatitis, Disseminated, OTHER ATOPIC DERMATITIS, Other atopic dermatitis and related conditions, allergic form of dermatitis, atopic dermatitis, atopic dermatitis and related conditions, dermatitis, atopic, eczema, eczema, atopic, eczematous dermatitis; Open Targets
Disease Ontology: DOID:3310; Disease Ontology
MeSH: D003876; MeSH
NCI Thesaurus: C3001; NCI Thesaurus
Highest stage of its drugs: Approval, for 42 of its 238 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs238

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DUPILUMAB	CHEMBL2108675	Antibody	Approval	ATC, EMA Human Drugs, FDA, PMDA and TTD	84	77	77	Drugs and targets
PIMECROLIMUS	CHEMBL1200686	Small molecule	Approval	ATC, DailyMed and TTD	41	37	37	Drugs and targets
CRISABOROLE	CHEMBL484785	Small molecule	Approval	ATC, DailyMed, FDA and TTD	35	30	30	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Approval	ATC and EMA Human Drugs	33	30	30	Drugs and targets
ABROCITINIB	CHEMBL3655081	Small molecule	Approval	ATC, EMA Human Drugs, FDA and TTD	27	23	23	Drugs and targets
LEBRIKIZUMAB	CHEMBL1743035	Antibody	Approval	ATC, EMA Human Drugs, FDA and PMDA	27	22	22	Drugs and targets
TRALOKINUMAB	CHEMBL1743081	Antibody	Approval	ATC, DailyMed, EMA Human Drugs, PMDA and TTD	25	20	20	Drugs and targets
UPADACITINIB	CHEMBL3622821	Small molecule	Approval	EMA Human Drugs	22	20	20	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Approval	ATC	18	16	16	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Approval	PMDA	15	14	14	Drugs and targets

1 to 10 of 238

See all 238 drugs

Targets126

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	28	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
HRH1	Histamine H1 receptor	15	Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
JAK1	Janus Kinase (JAK)	10	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
TYK2	Janus Kinase (JAK)	8	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Approval	https://conductscience.org/library/genes/7297	Drugs and targets
JAK2	Janus Kinase (JAK)	7	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	6	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Approval	https://conductscience.org/library/genes/3718	Drugs and targets
PDE4A	Phosphodiesterase 4	5	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	5	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	5	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	5	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5144	Drugs and targets

1 to 10 of 126

See all 126 targets

Trials603

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01949311	Open-label Study of Dupilumab in Patients With Atopic Dermatitis	Phase 3	2,733	2023-10-17	Atopic Dermatitis	DUPILUMAB	Its record names the disease	ClinicalTrials.gov
NCT00120523	5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis	Phase 3	2,418	2013-01-16	Atopic Dermatitis	HYDROCORTISONE, PIMECROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03587805	Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND	Phase 3	1,672	2025-01-16	Atopic Dermatitis	TRALOKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03334435	A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis	Phase 3	1,645	2022-07-01	Atopic Dermatitis	BARICITINIB	Its record names the disease	ClinicalTrials.gov
NCT03568318	A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	Phase 3	1,533	2022-03-31	Atopic Dermatitis	UPADACITINIB	Its record names the disease	ClinicalTrials.gov
NCT03627767	Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects	Phase 3	1,235	2021-09-20	Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases	ABROCITINIB	Its record names the disease	ClinicalTrials.gov
NCT04804605	Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis	Phase 3	1,220	2025-12-23	Atopic Dermatitis Eczema	ROFLUMILAST	Its record names the disease	ClinicalTrials.gov
NCT04392154	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	Phase 3	1,153	2025-08-03	Atopic Dermatitis	LEBRIKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03985943	Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis	Phase 3	941	2024-08-14	Moderate-to-Severe Atopic Dermatitis	NEMOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05601882	A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	Phase 3	920	2025-02-14	Atopic Dermatitis	DUPILUMAB, UPADACITINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 603

See all 603 trials

Comparisons in its trials266

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pimecrolimus vs Topical Corticosteroids: serious adverse events	247 of 1,205	210 of 1,213	2,418	NCT00120523	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16	87 of 601	8 of 197	798	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16	156 of 601	23 of 197	798	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16	95 of 601	14 of 197	798	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16	150 of 601	25 of 197	798	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16	250 of 601	42 of 197	798	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16	53 of 601	6 of 197	798	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16	177 of 597	28 of 195	792	NCT03131648	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.	198 of 591	29 of 201	792	NCT03160885	Trial comparisons
Tralokinumab 300 mg Q2W vs Placebo Q2W: Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16.	108 of 591	11 of 201	792	NCT03160885	Trial comparisons

1 to 10 of 266

See all 266 comparisons in its trials

Papers from its trials346

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42235562	RESULT	1	PubMed
39033766	RESULT	1	PubMed
38777187	RESULT	5	PubMed
37074705	RESULT	1	PubMed
34347860	RESULT	1	PubMed
32415720	RESULT	1	PubMed
31786154	RESULT	1	PubMed
30738171	RESULT	1	PubMed
28967549	RESULT	1	PubMed
27690741	RESULT	2	PubMed

1 to 10 of 346

See all 346 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004980

GET https://conductscience.org/api/diseases/v1/MONDO_0004980/drugs?page=2

API reference For AI assistants